1. HBW Insight
  2. >>Health
  3. >>Rx-to-OTC Switch

Label Comprehension Results Point Petros Toward OTC Self-Selection Study For Stendra ED Drug

 
• By Malcolm Spicer

Petros considers switch NDA for Stendra (avanafil), approved for Rx sales in US since 2012 on an NDA by Metuchen. Early indicators showed positive outcomes in a 453-subject label comprehension study for the oral PDE5 inhibitor.

• Source: Alamy

Petros Pharmaceuticals Inc. marks the first anniversary of its launch through the merger of Neurotrope Inc. and Metuchen Pharmaceuticals LLC with a report of strong OTC label comprehension results for an erectile dysfunction drug.

Petros is considering submitting a new drug application to the US Food and Drug Administration for an OTC switch of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rx-to-OTC Switch

More from Health